Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # FDA Removes 12 Peptides from 503A Category 2 Newtropin FDA July 2026 Peptide Meeting: What Patients Need to Know About Access, Approval, and Safety Meto blog FDA Schedules July 2026 PCAC Review of BPC 157, TB 500, MOTs C, KPV, Semax, Epitalon, DSIP PeptideRundown Dr Jesse Morse explains why BPC 157 will never receive FDA approval despite its potential to accelerate healing and recovery from injuries. >> More